Kepler Capital analyst David Evans maintained a Hold rating on Novo Nordisk (0QIU – Research Report) on January 13 and set a price target of ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

On Monday, Novo Nordisk A/S (NVO) stock saw a decline, ending the day at $84.62 which represents a decrease of $-1.64 or -1.90% from the prior close of $86.26. The stock opened at $84.42 and touched a ...

We recently published an article titled Jim Cramer Discussed These 21 Stocks As Bond Yields Soared. In this article, we are ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 503.77% and ...

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...

Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...

Eli Lilly (LLY) stock fell as its obesity therapy tirzepatide missed forecasts, amid focus on compounded weight loss ...

These stocks are all trading near their 52-week lows, and could be attractive options to consider. They all possess promising ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...